Serum Cystatin C as a Biomarker in Diffuse Large B-Cell Lymphoma

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Elevated serum cystatin C is linked to poor prognosis and metastasis in certain cancers.
• Understanding the role of cystatin C in hematological malignancies like DLBCL is crucial for potential biomarker development.

Purpose of the Study:

• To investigate the clinical significance of serum cystatin C levels in diffuse large B-cell lymphoma (DLBCL).
• To assess the correlation of cystatin C with disease characteristics and treatment response in DLBCL patients.

Main Methods:

• Serum cystatin C levels were measured in 58 DLBCL patients at diagnosis, 22 patients at remission, and healthy controls.
• Statistical analyses, including correlation with clinical factors and survival analysis (Kaplan-Meier curves), were performed.

Main Results:

• DLBCL patients exhibited significantly higher serum cystatin C levels than controls (p < 0.0001).
• Pretreatment cystatin C levels decreased significantly in patients achieving remission (p = 0.016).
• High cystatin C correlated with older age (>60), extra-nodal involvement (p = 0.005), and elevated LDH (p < 0.013).

Conclusions:

• Serum cystatin C may serve as a biomarker reflecting tumor burden in DLBCL.
• Elevated cystatin C levels in DLBCL are associated with extra-nodal involvement and decrease upon remission.
• Serum cystatin C levels at diagnosis do not appear to have prognostic significance for survival in DLBCL.